Rep. Matt Gaetz, Trump Ally, Sponsors Medical Pot Bill
*By Jacqueline Corba*
Freshman Congressman Matt Gaetz (R-FL) is on a mission to pass a bill that would allow for expanded medical marijuana research.
"Research can demystify who is right and who is wrong," Gaetz told Cheddar's CannaBiz Tuesday. "It's kind of nice to let the science guide our policy making."
Last week, the [Medical Marijuana Act](https://gaetz.house.gov/media/press-releases/congressman-matt-gaetz-applauds-passage-medical-cannabis-bill-through-house) sponsored by Gaetz passed the U.S. House Judicial Committee with bipartisan support.
It's a "landmark moment" Gaetz said; it's the first time Republicans in control of Congress have passed a medical marijuana bill through committee. Next it will head to the House floor for a vote.
"I'm super excited about what potential cannabis has in healthcare, and I think we'll learn a lot more if we're not so stupid as a government to make the research illegal," Gaetz said.
The act would give research institutions "safe harbor" to study the potential uses, benefits, and risks of the drug, which remains a Schedule I classification under the federal law alongside heroin and LSD.
"I think that marijuana policy has in many ways been victimized by the overall chilled relationship between the White House and the Department of Justice," Gaetz said.
"I think it is really Jeff Sessions who opposes medical marijuana, and I'm not entirely sure he and President Trump will be on one another's Christmas lists going forward."
For Gaetz, Washington is obstructing its own view.
"Washington just needs to get out of the way so that we can really see the potential."
For full interview [click here](https://cheddar.com/videos/medical-cannabis-research-act-passes-first-hurdle-in-congress).
The U.S. cannabis industry is on track to hit almost $25 billion in sales, according to New Frontier Data. Vivien Azer, managing director and senior research analyst at Cowen, and Russell Stanley, managing director and equity research at Beacon Securities Limited, join Cheddar News to give their predictions for the budding industry in 2022.
Rep. Earl Blumenauer (D-Ore. 3rd District), the co-chair of the Congressional Cannabis Caucus, joined Cheddar's "Cannabiz" to discuss the state of marijuana legalization on the federal level as more states continue to greenlight medical and adult use. He stated that there couldn't be a better time to revise the old policies on marijuana with more than 90 percent of Americans, including a majority of Republicans, on board. "This tidal wave of support continues. There were five states that approved in the last general election, and I think, rather than one single event, it is this momentum and the demonstration of broad public support that is making the difference," Blumenauer said.
Megan Horneman, Director of Portfolio Strategy at Verdence Capital Advisors, joins Cheddar News' Closing Bell, where she says there is some profit-taking ahead of the upcoming Fed meeting, and elaborates on some of the topics investors will be watching for more closely this week.
Rachel Bachman, senior sports reporter at the Wall Street Journal, joins Cheddar News' Closing Bell, where she explains how U.S. athletes have been inserted into the middle of a political debate after the country declared a diplomatic boycott of the upcoming Olympic Games in Beijing.
Lance Ippolito, Head Trader at the Future Of Wealth, joins Cheddar News' Closing Bell where he discusses the factors that have contributed to the recent slide of major cryptocurrencies like Bitcoin and Ether.
